Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Next Previous
Trial Profile

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FT 819 (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine
  • Indications Myositis; Systemic lupus erythematosus; Systemic scleroderma; Vasculitis
  • Focus Adverse reactions
  • Sponsors Fate Therapeutics

Most Recent Events

  • 06 Jul 2026 According to a Fate Therapeutics media release, company will present preliminary data on FT819 for systemic sclerosis from this phase I basket trial at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, being held at the Palais des congres de Montreal in Montreal, Canada on July 8 - 11, 2026.
  • 06 Jul 2026 Results presented in a Fate Therapeutics Media Release.
  • 13 May 2026 According to a Fate Therapeutics media release, as of 5 May 2026, Nineteen SLE patients across the two regimens have been treated, Eight patients have been treated across SSc, IIM and AAV. And, Of these 27 patients, 8 have been treated in an outpatient setting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top